A detailed history of Brevan Howard Capital Management LP transactions in 89bio, Inc. stock. As of the latest transaction made, Brevan Howard Capital Management LP holds 24,000 shares of ETNB stock, worth $173,760. This represents 0.0% of its overall portfolio holdings.

Number of Shares
24,000
Previous 12,281 95.42%
Holding current value
$173,760
Previous $142,000 35.21%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$7.31 - $10.9 $85,665 - $127,737
11,719 Added 95.42%
24,000 $192,000
Q1 2024

May 15, 2024

BUY
$8.13 - $13.77 $99,844 - $169,109
12,281 New
12,281 $142,000

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $337M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track Brevan Howard Capital Management LP Portfolio

Follow Brevan Howard Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brevan Howard Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Brevan Howard Capital Management LP with notifications on news.